ArticleBMC gastroenterology2025
The effect of longitudinal trajectories of triglyceride-glucose index on the incident metabolic dysfunction-associated steatotic liver disease.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe triglyceride-glucose (TyG) index is a reliable marker of insulin resistance and has been linked to metabolic disorders. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, particularly among older adults. The association between long-term changes in TyG levels and the risk of incident MASLD remains unclear. This study aimed to investigate the relationship between TyG index trajectories and the development of MASLD in the elderly.
methodsWe conducted a prospective cohort study involving 28,535 older adults who underwent annual health checkups from 2018 to 2021 with complete triglyceride and fasting blood glucose data. Group-based trajectory modeling was used to identify three distinct TyG trajectories: the low-stable, moderate-stable, and high-stable groups. MASLD incidence was assessed during follow-up visits in 2022 and 2023. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident MASLD across the trajectory groups. To minimize confounding, sensitivity analyses were conducted by excluding participants with a baseline body mass index (BMI) > 28 kg/m
resultsA total of 28,535 participants was included, comprising 13,456 males (47.16%) and 15,079 females (52.84%). The incidence rates of MASLD were 7.10% in the low-stable group, 16.10% in the moderate-stable group, and 23.20% in the high-stable group, increasing significantly with rising TyG trajectories (P < 0.001). After adjusting for age, sex, blood pressure, BMI, and lipid profiles, Cox regression models showed that the moderate-stable and high-stable groups had significantly higher risks of MASLD compared to the low-stable group, with HRs of 1.847 (95% CI: 1.699-2.008) and 2.361 (95% CI: 2.116-2.634), respectively (P < 0.001). A nonlinear dose-response relationship was also observed, with a sharp increase in MASLD risk when TyG index exceeded 8.54.
conclusionConsistently elevated TyG trajectories are associated with a significantly increased risk of incident MASLD, with the risk escalating progressively as TyG levels rise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.